---

Risk Factors of Arterial Hypertension

---

A. Non-Modifiable Risk Factors

1. Age

• BP rises progressively with age due to arterial stiffening (arteriosclerosis), reduced vascular compliance, and loss of elasticity in large vessels.
• Systolic hypertension becomes the dominant pattern after age 50 as pulse pressure widens.
• Prevalence rises from ~5% in those aged 20–40 to >65% in those over 65.

2. Sex

• Before age 50, hypertension is more common in men.
• After menopause, prevalence in women rises sharply and eventually surpasses men, due to loss of estrogen's vasodilatory and natriuretic effects.

3. Race / Ethnicity

• Black/African-American individuals have the highest prevalence of hypertension globally — it develops earlier, is more severe, and carries higher target-organ damage risk (stroke, CKD, LVH).
• Genetic differences in renin-angiotensin-aldosterone system (RAAS) activity, sodium retention, and endothelial function are implicated.

4. Family History / Genetic Factors

• Having a first-degree relative with hypertension approximately doubles the risk.
• Hypertension is polygenic; key genes involve RAAS regulation, sodium handling, and aldosterone synthesis.
• Rare monogenic forms include Liddle syndrome, Gordon syndrome, and glucocorticoid-remediable aldosteronism.

5. History of Preeclampsia / Gestational Hypertension

• Women with a history of preeclampsia carry a 2–4× higher lifetime risk of chronic hypertension, heart disease, and stroke (Living Kidney Donors Guidelines, p. 59).

---

B. Modifiable (Lifestyle) Risk Factors

1. Obesity and Overweight (BMI ≥25 kg/m²)

• Every 10 kg increase in body weight raises systolic BP by ~3–5 mmHg.
• Mechanisms: increased cardiac output, sympathetic nervous system (SNS) activation, hyperinsulinemia, increased renal sodium reabsorption, RAAS activation, and adipokine dysregulation (leptin resistance).
• Visceral/abdominal obesity (waist circumference >102 cm in men, >88 cm in women) is particularly strongly associated.

2. High Dietary Sodium Intake

• Strong dose-response relationship: each 2.3 g/day increase in sodium raises SBP by ~2–3 mmHg in normotensives and up to 4–8 mmHg in hypertensives ("salt-sensitive" individuals).
• Salt sensitivity is more common in older adults, Black individuals, those with CKD, and diabetics.
• Mechanism: volume expansion, increased preload, and impaired pressure natriuresis.

3. Physical Inactivity / Sedentary Behavior

• Physically inactive individuals have a 30–50% greater risk of developing hypertension.
• Regular aerobic exercise lowers SBP by 5–8 mmHg on average.
• Exercise improves endothelial function, reduces SNS activity, and promotes natriuresis.

4. Excess Alcohol Consumption

• Chronic heavy alcohol use (>2 standard drinks/day) raises BP directly.
• Alcohol raises BP via SNS activation, suppression of baroreceptors, increased cortisol, and endothelial dysfunction.
• Reducing intake from heavy to moderate lowers SBP by ~5–7 mmHg.
• Paradoxically, very low intake may have mild protective effects (debated).

5. Smoking and Tobacco Use

• Nicotine causes acute BP elevation via catecholamine release and vasoconstriction.
• Chronic smoking accelerates atherosclerosis, reduces arterial compliance, and promotes endothelial dysfunction — all amplifying hypertension risk.
• Smoking cessation is essential for cardiovascular risk reduction.

6. Dietary Patterns — Low Potassium, Low Calcium, Low Magnesium

• Potassium deficiency promotes sodium retention and vasoconstriction; increasing dietary potassium lowers BP by 3–5 mmHg.
• Low dietary calcium and magnesium are independently associated with elevated BP.
• The DASH (Dietary Approaches to Stop Hypertension) diet — rich in fruits, vegetables, whole grains, and low-fat dairy — lowers SBP by 8–14 mmHg.

7. Psychological Stress / Mental Health

• Chronic stress activates the hypothalamic-pituitary-adrenal axis and SNS, elevating catecholamines and cortisol.
• Depression and anxiety are independently associated with incident hypertension.
• Work-related stress and low socioeconomic status are also significant contributors.

8. Diabetes Mellitus and Insulin Resistance

• Insulin resistance leads to SNS activation, renal sodium retention, and RAAS upregulation.
• ~75% of patients with type 2 diabetes have hypertension.
• Hyperinsulinemia promotes vascular smooth muscle proliferation and endothelial dysfunction.

9. Dyslipidemia

• Elevated LDL-cholesterol promotes endothelial dysfunction and atherosclerosis, which reduces arterial compliance and raises blood pressure.
• Acts synergistically with hypertension to amplify cardiovascular risk.

---

C. Medication-Induced (Iatrogenic) Risk Factors

---

D. Secondary Causes of Hypertension

---

E. Special Population Considerations

---

Summary: Risk Factor Classification at a Glance

NON-MODIFIABLE          MODIFIABLE (Lifestyle)       SECONDARY CAUSES
─────────────────       ──────────────────────        ─────────────────────
Age                     Obesity                       Primary aldosteronism
Male sex (<50)          High sodium diet              Renovascular disease
Female sex (>50)        Physical inactivity           CKD
Race (Black)            Alcohol excess                OSA
Family history          Smoking                       Pheochromocytoma
Genetic variants        Low K/Ca/Mg diet              Cushing's syndrome
Preeclampsia hx         Stress/depression             Thyroid disorders
                        Diabetes/insulin resistance   Coarctation of aorta
                        Medications (NSAIDs, OCP…)

---

• Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (ACC/AHA 2017 Guidelines), p. 22
• Living Kidney Donors Guidelines, p. 59
• Harrison's Principles of Internal Medicine (background knowledge on pathophysiology)
• JNC 8 / ESC/ESH 2018 Hypertension Guidelines (background knowledge)

---

Arterial Hypertension — Detailed Explanation

---

1. Definition

Diagnosis requires confirmation on at least 2–3 separate occasions or validated by ambulatory/home monitoring.

---

2. Classification

ESC/ESH 2023 BP Classification

---

3. Epidemiology

• Affects approximately 1.28 billion adults worldwide (WHO, 2021).
• Prevalence is higher in low- and middle-income countries (~75% of cases).
• Rates increase sharply with age — over 65% prevalence in adults >65 years.
• Often called the "silent killer" — most patients are asymptomatic until complications develop.
• Responsible for ~10.4 million deaths per year globally, primarily from cardiovascular and cerebrovascular events.

---

4. Pathophysiology

BP = Cardiac Output (CO) × Total Peripheral Resistance (TPR)

A. Increased Cardiac Output

• Volume expansion (excess sodium/water retention)
• Sympathetic nervous system (SNS) hyperactivation → increased heart rate and contractility
• Insulin resistance → hyperinsulinemia → renal sodium retention

B. Increased Total Peripheral Resistance

• Endothelial dysfunction → reduced nitric oxide (NO) production → vasoconstriction
• Renin-Angiotensin-Aldosterone System (RAAS) overactivation → angiotensin II causes potent vasoconstriction + aldosterone-mediated sodium retention
• Vascular smooth muscle hypertrophy and remodeling
• Arterial stiffness (arteriosclerosis) with aging

Key Pathophysiological Pathways:

↑ Sodium intake / Obesity / Genetics
        ↓
RAAS activation → Angiotensin II ↑
        ↓
Vasoconstriction + Aldosterone ↑
        ↓
Na⁺/H₂O retention → ↑ Blood Volume
        ↓
↑ Cardiac Output + ↑ TPR
        ↓
HYPERTENSION
        ↓
Endothelial damage → Target Organ Damage

---

5. Types / Etiology

A. Primary (Essential) Hypertension (~90–95% of cases)

• No single identifiable cause
• Results from a complex interaction of genetic, environmental, and lifestyle factors
• Onset typically in the 4th–5th decade of life
• Diagnosis of exclusion

B. Secondary Hypertension (~5–10% of cases)

---

6. Clinical Features

A. Symptoms

• Headache (classically occipital, worse in the morning)
• Dizziness / lightheadedness
• Blurred vision
• Palpitations
• Epistaxis (nosebleeds)
• Tinnitus

B. Hypertensive Urgency vs. Emergency

---

7. Diagnosis

Measurement Methods

1. Office BP (OBP): Standard sphygmomanometer; average of 2 readings, 2 separate visits
2. Ambulatory BP Monitoring (ABPM): Gold standard — 24-hour recording; detects white-coat and masked hypertension
3. Home BP Monitoring (HBPM): 7-day morning and evening readings

Diagnostic Thresholds by Method

Evaluation Workup

• Urinalysis + urine albumin-to-creatinine ratio (renal damage)
• Serum creatinine + eGFR (CKD)
• Fasting glucose + HbA1c (diabetes)
• Lipid panel (cardiovascular risk)
• Serum electrolytes (K⁺ — hypokalemia suggests aldosteronism)
• ECG (LVH, arrhythmias)
• Thyroid function tests (secondary causes)
• Fundoscopy (hypertensive retinopathy)

---

8. Target Organ Damage (TOD)

Heart

• Left Ventricular Hypertrophy (LVH) → diastolic dysfunction → heart failure with preserved EF (HFpEF)
• Coronary artery disease → angina, myocardial infarction
• Atrial fibrillation
• Heart failure

Brain

• Ischemic stroke (most common)
• Hemorrhagic stroke / intracerebral hemorrhage
• Transient ischemic attack (TIA)
• Hypertensive encephalopathy (headache, confusion, seizures — PRES syndrome)
• Vascular dementia / cognitive decline

Kidneys

• Hypertensive nephrosclerosis → proteinuria → CKD → ESRD
• Bidirectional relationship: CKD worsens hypertension

Eyes

• Hypertensive Retinopathy — graded by Keith-Wagener-Barker classification:
  • Grade I: Arteriovenous nicking, silver-wiring
  • Grade II: AV nicking + focal arteriolar narrowing
  • Grade III: Flame hemorrhages, cotton-wool spots, hard exudates
  • Grade IV: Papilledema (hypertensive emergency)

Large Vessels

• Aortic aneurysm (abdominal and thoracic)
• Aortic dissection
• Peripheral artery disease

---

9. Management

A. Lifestyle Modifications (All Patients)

B. Pharmacological Treatment

Treatment Targets (ESC/ESH 2023):

C. Resistant Hypertension

• Add spironolactone (mineralocorticoid receptor antagonist) as 4th agent
• Screen for secondary causes (especially primary aldosteronism, OSA)
• Consider renal denervation (interventional option)

---

10. Prognosis and Cardiovascular Risk Stratification

---

11. Special Populations

---

Summary

Arterial hypertension is a multifactorial, chronic cardiovascular syndrome characterized by persistently elevated BP that silently damages the heart, brain, kidneys, and blood vessels over time. Early detection, comprehensive risk stratification, lifestyle modification, and individualized pharmacotherapy are the cornerstones of management.

---

• ESC 2024 / ESH 2023 Guidelines on Management of Arterial Hypertension (p. 8)
• Management of Primary Aldosteronism — Case Detection, Diagnosis, and Treatment (p. 10)
• ACC/AHA 2017 Guidelines on Prevention, Detection, Evaluation, and Management of High Blood Pressure
• Harrison's Principles of Internal Medicine; Braunwald's Heart Disease

---

Clinical Case Analysis — Male, 45 Years Old

---

TASK 1 — Diagnosis

Primary Diagnosis:

Primary (Essential) Arterial Hypertension, Grade 2, Stage II High cardiovascular risk Complication: Hypertension-Mediated Organ Damage (HMOD) — Left Ventricular Hypertrophy (LVH)

Justification:

Risk Factor Burden:

→ Multiple risk factors + HMOD (LVH) = HIGH cardiovascular risk category

Accompanying Diagnosis:

• Hypercholesterolemia / Mixed Dyslipidemia (total cholesterol ↑, LDL ↑, HDL low-normal, TG ↑)
• Obesity class I (BMI 32)

---

TASK 2 — Additional Examinations

1. Confirm sustained hypertension
2. Detect further target organ damage
3. Exclude secondary causes
4. Refine cardiovascular risk

A. To Confirm and Characterize Hypertension

B. To Detect Further Target Organ Damage (HMOD)

C. To Screen for Secondary Hypertension

Clinical note: In this patient, OSA is a particularly important secondary contributor to consider, given BMI 32 + sleep disturbance + fatigue.

---

TASK 3 — Differential Diagnosis — Conditions to Exclude

---

TASK 4 — Management Strategy

Step 1: Lifestyle Modification (MANDATORY — all patients, immediately)

---

Step 2: Antihypertensive Pharmacotherapy

Recommended First-Line Combination:

ACE Inhibitor (or ARB) + Calcium Channel Blocker (CCB) (preferred initial dual combination per ESH 2023 single-pill combination strategy)

Drugs to Avoid/Use Cautiously:

• Beta-blockers: Not first-line unless concurrent angina, AF, or HF with reduced EF
• Thiazide diuretics alone: May worsen dyslipidemia and glucose tolerance (use indapamide — more metabolically neutral)

---

Step 3: Manage Dyslipidemia (Cardiovascular Risk Reduction)

Start statin therapy — e.g., Rosuvastatin 10–20 mg OD or Atorvastatin 20–40 mg OD LDL target: <1.8 mmol/L (high CV risk per ESC guidelines) If TG remain elevated after LDL control: consider fenofibrate

---

Step 4: Address NSAID Use

• Patient uses NSAIDs periodically for headaches — advise to discontinue (NSAIDs raise BP by inhibiting vasodilatory prostaglandins and promoting sodium retention)
• Use paracetamol for headache management instead

---

Step 5: Follow-Up Plan

---

Summary Diagram

DIAGNOSIS
─────────────────────────────────────────────────────
Primary Arterial HTN, Grade 2, Stage II
(BP 160/100 + LVH on ECG/Echo)
HIGH Cardiovascular Risk
+ Dyslipidemia + Obesity Class I

MANAGEMENT
─────────────────────────────────────────────────────
1. Lifestyle: DASH diet, ↓ Na, ↓ alcohol,
   exercise, weight loss, stop NSAIDs

2. Antihypertensive: ACEi (Ramipril) +
   CCB (Amlodipine) → target <130/80 mmHg

3. Statin: Rosuvastatin/Atorvastatin
   → LDL target <1.8 mmol/L

4. Investigate: ABPM, urine ACR, eGFR,
   fundoscopy, sleep study (OSA), screen
   for secondary causes

5. Monitor: BP q4wk until target, then q6mo
   Echo at 12 months for LVH regression

---

• ESC 2024 / ESH 2023 Guidelines on Management of Elevated Blood Pressure and Hypertension (p. 38)
• ACC/AHA 2017 Guidelines — Prevention, Detection, Evaluation, and Management of High Blood Pressure (p. 51)
• Management of Primary Aldosteronism — Case Detection, Diagnosis, and Treatment
• Harrison's Principles of Internal Medicine; Braunwald's Heart Disease

---

Diagnostic Criteria for Ventricular Fibrillation (VF)

---

1. Definition

---

2. ECG — The Gold Standard for Diagnosis

Classic ECG Criteria:

The hallmark is the complete absence of any recognizable P-QRS-T morphology, replaced by irregular, rapid, chaotic waveforms of varying shape, amplitude, and frequency.

---

ECG Example — Classic Ventricular Fibrillation:

---

3. Types of VF — ECG Classification

---

4. Clinical Diagnostic Criteria

Signs and Symptoms:

Clinical diagnosis of VF = Cardiac arrest + Shockable rhythm confirmed on cardiac monitor

---

5. Diagnostic Approach — Step by Step

STEP 1: Recognize cardiac arrest
        ↓ Unresponsive, no normal breathing, no pulse (< 10 sec check)

STEP 2: Activate emergency response + Start CPR immediately

STEP 3: Attach cardiac monitor / defibrillator AS SOON AS AVAILABLE
        ↓
STEP 4: Analyze rhythm on monitor
        ↓
        Is it chaotic, irregular, no P-QRS-T?
        ↓ YES
STEP 5: CONFIRM VF in ≥2 leads (rule out artifact or fine VF vs asystole)
        ↓
STEP 6: SHOCK — Immediate unsynchronized defibrillation

---

6. Differentiating VF from Other Rhythms

---

7. Etiology (Causes to Identify)

Cardiac Causes (most common):

• Acute myocardial infarction (MI) — most frequent trigger
• Structural heart disease: dilated cardiomyopathy, hypertrophic cardiomyopathy
• Left ventricular hypertrophy / heart failure
• Valvular heart disease (aortic stenosis)
• Prior cardiac arrest / prior VF
• Congenital channelopathies: Brugada syndrome, Long QT syndrome, Short QT syndrome, Catecholaminergic Polymorphic VT (CPVT)
• Wolff-Parkinson-White syndrome with rapid AF

Non-Cardiac / Reversible Causes ("H's and T's"):

---

8. Pathophysiology

Trigger (ischemia, ion channel mutation, electrolyte imbalance, etc.)
        ↓
Multiple re-entry circuits form in ventricular myocardium
        ↓
Electrical wavelets spiral chaotically through ventricles
        ↓
No uniform depolarization → No coordinated contraction
        ↓
Ventricular quivering → Zero cardiac output
        ↓
Cerebral perfusion ceases → LOC within seconds
        ↓
Biological death within 4–6 minutes without intervention

---

9. Immediate Management (ACLS Protocol)

Shockable Rhythm → Immediate Defibrillation is the definitive treatment

Refractory VF:

---

10. Prognosis

Overall survival to hospital discharge for out-of-hospital VF: ~25–40% with optimal response chain; drops to <5% without bystander CPR.

---

Summary

---

• Optimal Post Cardiac Arrest and Refractory Cardiac Arrest Patient Care (p. 11) — DOSE VF trial data
• ECG images: PMC Clinical VQA Dataset — validated clinical ECG tracings
• AHA ACLS Guidelines 2020/2023; Harrison's Principles of Internal Medicine; Braunwald's Heart Disease